Skip to Content

AVEO Oncology

Merger

  • Date:
  • 10/18/2022
  • Company Name:
  • AVEO Oncology
  • Stock Symbol:
  • AVEO
  • Company Name - Buyer:
  • LG Chem, Ltd.
  • Stock Symbol - Buyer:
  • 051910
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/18/2022

Case Finder

Locate any case using the tools below.

NEW YORK, October 18, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of AVEO Oncology (NASDAQ: AVEO) (“AVEO”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by LG Chem, Ltd. (KOSPI: 051910) (“LG Chem”).

On October 18, 2022, AVEO announced that it had entered into an agreement to be acquired by LG Chem in an all-cash transaction deal valued at $566 million. Pursuant to the merger agreement, LG Chem will acquire AVEO for $15.00 per share in cash. The deal is expected to close in early 2023.

Bragar Eagel & Squire is concerned that AVEO’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for AVEO’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in AVEO Oncology. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: